Skip to content
Screener

BridgeBio Pharma BBIO Cash & Equivalents

Cash & Equivalents at other companies

Pfizer logo
PfizerPFE
$1.76B+18.8%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$350.07M+17.7%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$874.01M-28.0%
ALN
Alnylam PharmaceuticalsALNY
$1.71B+53.2%
Celcuity logo
CelcuityCELC
$145.19M+781%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$815.44M+103%

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$16.06B+87.5%
Enterprise value$18.44B+136%
P/S27.7×-8.6×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:31 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001743881-26-000019
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Unpaid property and equipment$12$337
Transfers to noncontrolling interests$(1,955)$(824)
Recognized intangible asset recorded to “Other current liabilities”$4,500
Reconciliation of Cash, Cash Equivalents and Restricted Cash:
Cash and cash equivalents$879,891$540,599
Restricted cash — Included in “Prepaid expenses and other current assets”550126
Restricted cash — Included in “Other assets”1,5772,017
Total cash, cash equivalents and restricted cash at end of periods shown on the condensed consolidated statements of cash flows$882,018$542,742

Item 1. Financial Statements (Unaudited)

FAQ

What is BridgeBio Pharma's cash & equivalents?
BridgeBio Pharma (BBIO) reported cash & equivalents of $882.02M in Q1 2026.
How has BridgeBio Pharma's cash & equivalents changed year-over-year?
BridgeBio Pharma's cash & equivalents increased by 62.5% year-over-year, from $542.74M to $882.02M.
What is the long-term trend for BridgeBio Pharma's cash & equivalents?
Over 5 years (2020 to 2025), BridgeBio Pharma's cash & equivalents has grown at a -13.7% compound annual growth rate (CAGR), from $356.08M to $170.49M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about BridgeBio Pharma's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude